Nuvation Bio Inc. financial data

Symbol
NUVB, NUVB-WT on NYSE
Industry
Pharmaceutical Preparations
Location
357 Tehama Street, Floor 3, San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Panacea Acquisition Corp (to 2/11/2021)
Latest financial report
10-Q - Q2 2024 - Aug 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.51K % -49.4%
Debt-to-equity 5.68 % +115%
Return On Equity -184 % -1221%
Return On Assets -155 % -1039%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 249M shares +13.8%
Common Stock, Shares, Outstanding 249M shares +13.6%
Entity Public Float 261B USD -44.3%
Common Stock, Value, Issued 1.08B USD +14.9%
Weighted Average Number of Shares Outstanding, Basic 245K shares +11.8%
Weighted Average Number of Shares Outstanding, Diluted 245K shares +11.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.44M USD
Research and Development Expense 76M USD +0.61%
General and Administrative Expense 28.2M USD -12.5%
Operating Income (Loss) -538M USD -406%
Nonoperating Income (Expense) 27M USD +69.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -511M USD -465%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -954M USD -955%
Earnings Per Share, Basic -2.12 USD/shares -417%
Earnings Per Share, Diluted -2.12 USD/shares -417%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 34.3M USD -31.5%
Marketable Securities, Current 543M USD -6.53%
Assets, Current 587M USD -7.86%
Property, Plant and Equipment, Net 751K USD -6.59%
Operating Lease, Right-of-Use Asset 2.72M USD -16%
Other Assets, Noncurrent 1.08M USD
Assets 595M USD -7.27%
Accounts Payable, Current 5.21M USD +102%
Accrued Liabilities, Current 20M USD +109%
Contract with Customer, Liability, Current 12.2M USD
Liabilities, Current 51.1M USD +281%
Contract with Customer, Liability, Noncurrent 9.16M USD
Accrued Income Taxes, Noncurrent 144K USD +28.6%
Operating Lease, Liability, Noncurrent 972K USD -59.4%
Liabilities 62.7M USD +273%
Common Stocks, Including Additional Paid in Capital 117M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.27M USD +71.2%
Retained Earnings (Accumulated Deficit) -820M USD -165%
Stockholders' Equity Attributable to Parent 257M USD -58.8%
Liabilities and Equity 595M USD -7.27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.7M USD +18.8%
Net Cash Provided by (Used in) Financing Activities 21K USD -93%
Net Cash Provided by (Used in) Investing Activities 7.54M USD
Common Stock, Shares Authorized 1.06B shares 0%
Common Stock, Shares, Issued 249M shares +13.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.14M USD +88.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 34.3M USD -31.5%
Deferred Tax Assets, Valuation Allowance 100M USD +18%
Deferred Tax Assets, Gross 101M USD +17.7%
Operating Lease, Liability 3.05M USD -17.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -508M USD -478%
Lessee, Operating Lease, Liability, to be Paid 3.22M USD -19.5%
Property, Plant and Equipment, Gross 1.38M USD +2.29%
Operating Lease, Liability, Current 2.08M USD +61.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.42M USD -5.28%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.1M USD +51.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +16.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 173K USD -46.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 629K USD -41.3%
Deferred Tax Assets, Operating Loss Carryforwards 29.3M USD +32%
Unrecognized Tax Benefits 5.63M USD +11.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 81K USD -87.2%
Share-based Payment Arrangement, Expense 23.8M USD +29.9%
Interest Expense 132K USD